CORONA Remedies
CORONANSE

CORONA Remedies

₹1,743.30-2.50 (0.14%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
1,719.00
Today’s high
1,755.00
52 week low
1,336.60
52 week high
1,790.00
Open price
1,755.00
Previous close
1,745.80
Live volume
4,035
Lower circuit
1,396.70
Upper circuit
2,094.90

Fundamentals

Market Cap
₹10,682Cr
ROE
26.53%
P/E Ratio(TTM)
62.33
EPS(TTM)
28.02
P/B Ratio
16.19
Dividend Yield
0.42%
Industry P/E
33.75
Book Value
107.86
Debt to Equity
0.10
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
DEC '25
Revenue (Cr)
₹345
-5.16%
Profit (Cr)
₹41.27
-21.12%
0100200300400
Sep '24
Dec '24
Jun '25
Sep '25
Dec '25

About

CORONA Remedies Limited is a pharmaceutical company focused on women's health, cardio-metabolic, and other therapeutic segments, manufacturing and marketing branded formulations.;
CEO/MD
Niravkumar Kirtikumar Mehta
Founded in
2004
NSE symbol
CORONA

Shareholding Pattern

Apr '25
Dec '25
Mar '26
Promoters
69.00%
Foreign Institutions
22.01%
Mutual Funds
6.35%
Retail And Others
1.98%
Other Domestic Institutions
0.67%

Mutual Funds Invested (4)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹1,380.00
+8.10 (0.59%)
L
    H
    19,001.1640.365.41
    ₹747.25
    +11.25 (1.53%)
    L
      H
      18,236.6130.653.59
      ₹956.00
      -0.50 (0.05%)
      L
        H
        15,215.5435.432.31
        ₹1,118.70
        -6.30 (0.56%)
        L
          H
          13,788.8225.364.57
          Livesquawk
          Corona Remedies reports OCF to EBITDA ratio at 87%, indicating strong cash conversion. The company highlights room for further acquisitions supported by its financial metrics.
          Livesquawk
          Corona Remedies reports ₹112 Cr cash as of Dec 31, 2022. Targets 20-25% CAGR growth for Wpladone over the next 3 years.
          2026
          11
          May
          Quarterly & Annual Result
          Upcoming
          Release date
          2
          Feb
          Quarterly Result
          Release date
          2
          Jan
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks